In combination w/ other approved chemotherapeutic agents in patients w/ refractory testicular tumors who have already received appropriate surgical, chemotherapeutic & radiotherapeutic therapy. In combination w/ other approved chemotherapeutic agents as 1st line treatment in patients w/ small cell lung cancer. Management of Hodgkin's disease, malignant (non-Hodgkin's) lymphomas, especially of the histiocytic variety, acute non-lymphocytic leukemia.
IV infusion Usually over a 30-60 min period. Refractory testicular tumors, Hodgkin's disease, malignant (non-Hodgkin's) lymphomas, especially of the histiocytic variety, acute non-lymphocytic leukemia Range: 50-100 mg/m2 daily on days 1-5 to 100 mg/m2 daily on days 1, 3 & 5. Small cell lung cancer Range: 35 mg/m2 daily for 4 days to 50 mg/m2 daily for 5 days. Repeat chemotherapy courses at 3- to 4-wk intervals after adequate recovery from any toxicity.
Risk of severe myelosuppression w/ resulting infection or bleeding. Frequently observe patients for myelosuppression during & after therapy. Risk of anaphylaxis. Mutagenic & genotoxic potential. Consider potential carcinogenicity. Can cause fetal harm when administered to a pregnant woman. Discontinue breastfeeding or abstain from therapy taking into account the importance of the drug to the mother. Safety & efficacy in childn have not been established.
Rare reports of acute leukaemia w/ other antineoplastic drugs eg, bleomycin, cisplatin, ifosfamide & MTX. Patient's Ab response to inactivated vaccine may be decreased. Concurrent use w/ a live virus vaccine may potentiate replication of the vaccine virus, may increase adverse effects of the vaccine virus, &/or may decrease patient's Ab response to the vaccine.
L01CB01 - etoposide ; Belongs to the class of plant alkaloids and other natural products, podophyllotoxin derivatives. Used in the treatment of cancer.
Sign Out
